We know it hasn't been easy and we appreciate you.
The pandemic upended our lives and how you practice veterinary medicine. Looking back, we’re extremely proud of our team, our community, and our industry for the way it has adjusted to incredible circumstances and still delivered medicine with care and compassion.
Dr. Elizabeth Iorns is a scientist whose research focuses on identifying mechanisms of breast cancer progression. She is a cofounder and CEO of Science Exchange, and she helped launch the Reproducibility Initiative. She was involved in the development of Olaparib, a targeted therapy directed at the BRCA1 and BRCA2 mutation, best known for its relation to breast cancer (and recently added to the FidoCure® platform).
The following medical brief espouses how ordinary clinical trial design is rendered less than perfect for targeted therapies, and suggests how the following 3 interrelated Agile Trial Design principles should be considered:
With new research and medical advancements, immunotherapy is the new frontier in veterinary oncology.
Please join us in welcoming Dr. Nicola Mason, B.Vet.Med,...
In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.
In veterinary cancer care, it’s common to come across tough clinical questions where there is no known right answer.
In veterinary cancer care, it’s common to come across tough clinical questions where there is no known right answer. A few examples include:
Mental health for veterinary professionals can be a challenge in the best of times and even more so during the stressful COVID-19 pandemic. Many of us are concerned with keeping our teams mentally healthy and happily engaged.
In the seventh webinar of this series, we welcome Dr. Carrie Jurney, DVM, DACVIM (Neurology), President of Not One More Vet, a non-profit supporting the mental health of veterinary professionals. She highlights the history of mental health in the veterinary community and delves into its effects during the global pandemic. Dr. Jurney discusses best practices and potential solutions, and provides answers to some of your most asked questions.
In our fifth webinar of this series, we welcome Joe Costa, COO of Wedgewood Pharmacy, to discuss the effects of the COVID-19 pandemic on the veterinary compounding pharmaceutical industry. Joe will share how Wedgewood has been able to deliver for veterinarians and their patients despite COVID-19 disruption.
In the second segment of our third webinar, Dr. Pamela Schwartz shared experiences from the epicenter of the US COVID-19 crisis: New York City. Dr. Schwartz is the Chair of Department of Surgery, Soft Tissue & Orthopedics at the Animal Medical Center, the largest animal hospital in NY. Leading the surgery department at the largest animal hospital in New York is a challenge in normal days, let alone during a global pandemic. Dr. Schwartz shared how her hospital is handling the logistical, medical, and emotional challenges posed by the current situation.
